TIME-2b Disappointed: Aerpio’s Lead Product Fails In Diabetic Retinopathy
Executive Summary
As its lead product fails at Phase IIb in diabetic retinopathy, Aerpio’s attentions turn to its other potential indications, but investors will need more convincing that this strategy will pay dividends.
You may also be interested in...
Finance Watch: Phathom IPO Meets Pricing Goal; Cabaletta, TFF Offerings Go Low
Public Company Edition: Phathom went public in the US within proposed pricing terms, but Cabaletta’s IPO went to market below a proposed range, while TFF launched in line with earlier plans. Also, Principia’s FOPO raises $210m and Trillium restructures.
Five Late-Breaking Studies To Look Out For At ASCO
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.
China Takes A Bigger Role In The World Pharma Stage
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.